Pneumonitis as an early complication of alemtuzumab treatment (P5.406)

Conclusions:Pneumonitis, while rare, resolves with corticosteroids and may occur earlier in the course of alemtuzumab treatment than previously suspected. Despite pneumonitis, patients’ MS may remain under good control.Disclosure: Dr. Kantor has received personal compensation for activities with Avanir, Bayer, Biogen, EMD Serono, Abbvie, Genzyme, Malinckrodt, Novartis, Otsuka, and Sandoz as consulting services and/or speakig honoraria. Dr. Steingo has received personal compensation for activities with Biogen, TEVA, Novartis, EMD Serono, Acorda, Sanofi Genzyme, Mallinckrodt as as speaker and/or advisor. Dr. Steingo has received research support from Sanofi Genzyme, Novartis, Mallinckrodt, and MedDay.
Source: Neurology - Category: Neurology Authors: Tags: Disease Modifying Therapy for Multiple Sclerosis: Risk Assessment and Safety Source Type: research